Anti-ELMO1 + ELMO2 antibody [EPR13567],Abcam,AB181234

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

WB

Platform ID

BAB666791724

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-ELMO1 + ELMO2 antibody [EPR13567]
Cat. No.AB181234
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB
ClonalityMonoclonal
Clone NumberEPR13567
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Acts in association with DOCK1 and CRK. Was initially proposed to be required in complex with DOCK1 to activate Rac Rho small GTPases. May enhance the guanine nucleotide exchange factor (GEF) activity of DOCK1. See full target information ELMO2 Additional targets ELMO1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.